meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - 1st line (L1)
mOC - L1 - all population
1
mOC - L1 - PDL1 positive
1
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">Standard of Care (SoC)</span>
<span style="margin-left: 2em;">placebo plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">atezolizumab based treatment</span>
<span style="margin-left: 3em;">atezolizumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (2)
progression or deaths (PFS) (2)
objective responses (ORR) (2)
AE (any grade) (1)
TRAE (any grade) (1)
SAE (any grade) (1)
AE leading to treatment discontinuation (any grade) (1)
TRAE (grade 3-4) (1)
AE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
AE leading to death (grade 5) (1)
STRAE (any grade) (1)
Rash TRAE (grade 3-4) (1)
Colitis TRAE (grade 3-4) (1)
Hepatitis TRAE (grade 3-4) (1)
Hypothyroidism TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Adrenal insufficiency TRAE (grade 3-4) (1)
Diabetes TRAE (grade 3-4) (1)
Severe skin reaction TRAE (grade 3-4) (1)
Pancreatitis TRAE (grade 3-4) (1)
Nephritis TRAE (grade 3-4) (1)
Myositis TRAE (grade 3-4) (1)
Myocarditis TRAE (grade 3-4) (1)
Infusion-related reactions TRAE (grade 3-4) (1)
Guillain-Barré syndrome TRAE (grade 3-4) (1)
Decreased appetite AE (grade 3-4) (1)
Dyspnoea AE (grade 3-4) (1)
Hypertension AE (grade 3-4) (1)
Proteinuria AE (grade 3-4) (1)
Acute kidney injury AE (grade 3-4) (1)
Infusion-related reaction AE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Evidence network for deaths_(OS)
2
IMagyn-050 (all population), 2021 IMagyn-050 (PDL1 >1%), 2021
placebo plus SoC
atezolizumab plus SoC
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
placebo plus SoC
atezolizumab plus SoC
placebo plus SoC
---
NA
atezolizumab plus SoC
NA
---
pathologies: 247,249,250 - treatments: 866
result logic
×
Study list
